SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag

Published on 18 Feb 2025 on Zacks · via Yahoo Finance

The sBLA is based on data from a pivotal study that demonstrated that Dupixent led to significant...

Read the rest of the article

Start tracking your investments with Statfolio

AstraZeneca expects Farxiga and Lynparza to be included in the volume-based procurement plans in...

Zacks · via Yahoo Finance 20 Feb 2025

BMRN reports better-than-expected fourth-quarter results, driven by encouraging uptake for Voxzog...

Zacks · via Yahoo Finance 20 Feb 2025

Zealand Pharma stock falls loss widens, revenue declines

Investing.com 20 Feb 2025

(Bloomberg) -- European stocks suffered their biggest decline in two months, hit by the possibili...

Bloomberg · via Yahoo Finance 19 Feb 2025

The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere,...

BioPharma Dive · via Yahoo News 19 Feb 2025

The sBLA is based on data from a pivotal study that demonstrated that Dupixent led to significant...

Zacks · via Yahoo Finance 18 Feb 2025

PFE, NVS and ABBV have a Zacks Rank #3 (Hold) each, while Sanofi and RHHBY have a Zacks Rank #4...

Zacks · via Yahoo Finance 14 Feb 2025

France stocks higher at close of trade; CAC 40 up 0.18%

Investing.com 14 Feb 2025

CRSP beat on earnings in three of the trailing four quarters and missed the mark in the other,...

Zacks · via Yahoo Finance 3 Feb 2025

Sanofi is not the only big pharma company targeting a share buyback campaign. On the back of boom...

Pharmaceutical Technology · via Yahoo Finance 3 Feb 2025